Literature DB >> 31399519

A Novel Vaccine Strategy to Overcome Poor Immunogenicity of Avian Influenza Vaccines through Mobilization of Memory CD4 T Cells Established by Seasonal Influenza.

Anthony T DiPiazza1, Shufang Fan2, Ajitanuj Rattan1, Marta L DeDiego1, Francisco Chaves1, Gabriele Neumann2, Yoshihiro Kawaoka3, Andrea J Sant4.   

Abstract

Avian influenza vaccines exhibit poor immunogenicity in humans. We hypothesized that one factor underlying weak B cell responses was sequence divergence between avian and seasonal influenza hemagglutinin proteins, thus limiting the availability of adequate CD4 T cell help. To test this, a novel chimeric hemagglutinin protein (cH7/3) was derived, comprised of the stem domain from seasonal H3 hemagglutinin and the head domain from avian H7. Immunological memory to seasonal influenza was established in mice, through strategies that included seasonal inactivated vaccines, Flumist, and synthetic peptides derived from the H3 stalk domain. After establishment of memory, mice were vaccinated with H7 or cH7/3 protein. The cH7/3 Ag was able to recall H3-specific CD4 T cells, and this potentiated CD4 T cell response was associated with enhanced early germinal center response and rapid elicitation of Abs to H7, including Abs specific for the H7 head domain. These results suggest that in pandemic situations, inclusion of CD4 T cell epitopes from seasonal viruses have the potential to overcome the poor immunogenicity of avian vaccines by helping B cells and conferring greater subtype-specific Ab response to viral HA.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31399519      PMCID: PMC6737897          DOI: 10.4049/jimmunol.1900819

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

1.  Cutting edge: CD4 T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus.

Authors:  Katherine A Richards; David Topham; Francisco A Chaves; Andrea J Sant
Journal:  J Immunol       Date:  2010-10-01       Impact factor: 5.422

Review 2.  Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults.

Authors:  Natalie J Carter; Monique P Curran
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

3.  Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes.

Authors:  Rong Hai; Florian Krammer; Gene S Tan; Natalie Pica; Dirk Eggink; Jad Maamary; Irina Margine; Randy A Albrecht; Peter Palese
Journal:  J Virol       Date:  2012-03-07       Impact factor: 5.103

4.  Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine.

Authors:  Gary J Nabel; Anthony S Fauci
Journal:  Nat Med       Date:  2010-12       Impact factor: 53.440

5.  Vaccines for seasonal and pandemic influenza.

Authors:  Kristin L Nichol; John J Treanor
Journal:  J Infect Dis       Date:  2006-11-01       Impact factor: 5.226

6.  Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus.

Authors:  Michelle Roti; Junbao Yang; DeAnna Berger; Laurie Huston; Eddie A James; William W Kwok
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

7.  Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.

Authors:  Nega Ali Goji; Carrie Nolan; Heather Hill; Mark Wolff; Diana L Noah; Tracy B Williams; Thomas Rowe; John J Treanor
Journal:  J Infect Dis       Date:  2008-09-01       Impact factor: 5.226

8.  Infection of HLA-DR1 transgenic mice with a human isolate of influenza a virus (H1N1) primes a diverse CD4 T-cell repertoire that includes CD4 T cells with heterosubtypic cross-reactivity to avian (H5N1) influenza virus.

Authors:  Katherine A Richards; Francisco A Chaves; Andrea J Sant
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

9.  Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals.

Authors:  Laurel Yong-Hwa Lee; Do Lien Anh Ha; Cameron Simmons; Menno D de Jong; Nguyen Van Vinh Chau; Reto Schumacher; Yan Chun Peng; Andrew J McMichael; Jeremy J Farrar; Geoffrey L Smith; Alain R M Townsend; Brigitte A Askonas; Sarah Rowland-Jones; Tao Dong
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

Review 10.  A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses.

Authors:  Benoit Baras; Nancy Bouveret; Jeanne-Marie Devaster; Louis Fries; Paul Gillard; Roland Sänger; Emmanuel Hanon
Journal:  Influenza Other Respir Viruses       Date:  2008-11       Impact factor: 4.380

View more
  5 in total

Review 1.  Influenza B: Prospects for the Development of Cross-Protective Vaccines.

Authors:  Liudmila M Tsybalova; Liudmila A Stepanova; Edward S Ramsay; Andrey V Vasin
Journal:  Viruses       Date:  2022-06-17       Impact factor: 5.818

2.  Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools.

Authors:  Anne S De Groot; Leonard Moise; Frances Terry; Andres H Gutierrez; Pooja Hindocha; Guilhem Richard; Daniel Fredric Hoft; Ted M Ross; Amy R Noe; Yoshimasa Takahashi; Vinayaka Kotraiah; Sarah E Silk; Carolyn M Nielsen; Angela M Minassian; Rebecca Ashfield; Matt Ardito; Simon J Draper; William D Martin
Journal:  Front Immunol       Date:  2020-04-07       Impact factor: 7.561

3.  Strong influenza-induced TFH generation requires CD4 effectors to recognize antigen locally and receive signals from continuing infection.

Authors:  Priyadharshini Devarajan; Allen M Vong; Catherine H Castonguay; Olivia Kugler-Umana; Bianca L Bautista; Michael C Jones; Karen A Kelly; Jingya Xia; Susan L Swain
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-22       Impact factor: 12.779

4.  The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination.

Authors:  Johannes B Goll; Aarti Jain; Travis L Jensen; Rafael Assis; Rie Nakajima; Algis Jasinskas; Lynda Coughlan; Sami R Cherikh; Casey E Gelber; S Khan; D Huw Davies; Philip Meade; Daniel Stadlbauer; Shirin Strohmeier; Florian Krammer; Wilbur H Chen; Philip L Felgner
Journal:  NPJ Vaccines       Date:  2022-08-30       Impact factor: 9.399

5.  Intranasal Nanoparticle Vaccination Elicits a Persistent, Polyfunctional CD4 T Cell Response in the Murine Lung Specific for a Highly Conserved Influenza Virus Antigen That Is Sufficient To Mediate Protection from Influenza Virus Challenge.

Authors:  Sean A Nelson; Thamotharampillai Dileepan; Amy Rasley; Marc K Jenkins; Nicholas O Fischer; Andrea J Sant
Journal:  J Virol       Date:  2021-07-26       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.